Pharma BD Deal Intelligence

Oak Hill Bio (OHB Pediatrics Ltd.) / Research Alliance Corporation III

2026 · Reverse Merger · $175M · Pending

OHB Pediatrics Ltd. (d/b/a Oak Hill Bio) and Research Alliance Corporation III, a SPAC sponsored by RA Capital Management, announced a definitive business combination agreement on 2026-07-27. The transaction is expected to provide approximately $175 million in gross proceeds, comprising $75 million of cash in the SPAC trust account fully backstopped by RA Capital Management and a $100 million committed private financing. Combined with Oak Hill Bio's $32.5 million Series A, proceeds are expected to fund rugonersen through Phase 3 readout and a potential NDA submission in 2H2029. Rugonersen is an investigational antisense oligonucleotide for Angelman syndrome licensed from Roche, now in the pivotal Phase 3 BEACON trial which dosed its first patient in July 2026. The combined company is expected to trade on the Nasdaq Capital Market as 'OAKH' with closing expected by year-end 2026.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals